Quarterly report pursuant to Section 13 or 15(d)

BUSINESS COMBINATIONS AND ASSET PURCHASES - Schedule of preliminary purchase consideration (Details)

v3.23.2
BUSINESS COMBINATIONS AND ASSET PURCHASES - Schedule of preliminary purchase consideration (Details) - USD ($)
 1 Months Ended 6 Months Ended
Feb. 21, 2023
Apr. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Cash consideration:        
Net cash consideration     $ 2,987,000 $ 12,746,000
Kind Therapeutics USA LLC.        
Cash consideration:        
Cash paid at closing   $ 13,500,000    
Cash paid at closing   10,128,000    
Release of escrow   2,444,000    
Severance paid from escrow   556,000    
Less cash acquired   (2,310,000)    
Net cash consideration   10,818,000    
Promissory note   5,634,000    
Write-off accounts receivable   658,000    
Write-off of deferred accounts receivable   842,000    
Total fair value of consideration transferred   $ 17,952,000    
Ermont Acquisition        
Cash consideration:        
Cash paid at closing $ 3,000,000      
Less cash acquired (13,000)      
Net cash consideration 2,987,000      
Common stock 2,994,000      
Promissory note 4,569,000      
Total fair value of consideration transferred $ 10,550,000   $ 13,000,000